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A major challenge for living organisms is to maintain 
homeostasis in response to changes in external and inter-
nal environments. These include alterations in nutrient 
and water supplies, physical stress, temperature changes, 
physiological stress, infections and malignancies1. 
Through billions of years of evolution, the forms of life 
and biological processes that cope with these challenges 
in the most successful way have been selected. One chal-
lenge that all organisms have to deal with is the elimina-
tion of microorganisms and of abnormal or damaged 
cellular material. The ideal immune response would 
eliminate the potential threat and re-establish home-
ostasis without causing excessive damage to healthy 
cells and tissues. However, immune responses to infec-
tions are often disruptive and can cause marked tissue 
damage2,3. Such responses are evolutionarily advan-
tageous when the benefit of eliminating the challenge 
outweighs the risk of associated tissue damage and the 
requirement for regeneration. However, for potential 
challenges that occur frequently but rarely develop into 
serious homeostasis-altering threats, it is not desirable 
to mount systemic or potentially disruptive immune 
responses. In addition, vigorous immune responses are 
not desirable in organs and tissues that are particularly 
sensitive to immune-mediated damage, such as the 
brain. Therefore, the ideal immune response has checks 
and balances, which allow the organism to modulate the 
magnitude and duration of the response according to the 
nature of the threat caused by the challenge.
The mammalian immune system, as we understand 
it today, is induced mainly by two types of receptor sys-
tems, the germline-encoded pattern recognition receptors 
(PRRs), which initiate innate immune responses, and 
the antigen-specific receptors generated through gene 
rearrangement after antigen encounter, which initiate 
adaptive immune responses4–6. The immune responses 
induced by PRRs, such as Toll-like receptors (TLRs), 
interact with those induced by antigen-specific recep-
tors; this interaction is notably represented by dendritic 
cells, which rely on PRR-driven cues to initiate den-
dritic cell maturation for the stimulation of lympho-
cytes through antigen-specific receptors5. However, 
the research literature contains numerous reports of 
host defence activities that occur independently of both 
PRR-based immunity and antigen-specific receptors7–10, 
and emerging evidence suggests that several of these 
mechanisms have non-redundant roles in host defence 
in humans11,12. Here we review the literature on this topic 
by focusing on constitutive immune mechanisms. On the 
basis of this analysis, and by integrating concepts previ-
ously reviewed13, we propose that this constitutive layer 
of innate immunity exerts early host defence activities 
through specific molecular mechanisms and at the same 
time limits PRR activation as a specific feature.
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The inducible responses of pattern recognition receptors of the innate immune system and 
antigen-specific receptors of the adaptive immune system are highly effective, but they also 
have the potential to cause extensive immunopathology and tissue damage, as seen in many 
infectious and autoinflammatory diseases. By contrast, constitutive innate immune mechanisms, 
including restriction factors, basal autophagy and proteasomal degradation, tend to limit 
immune responses, with loss-of-function mutations in these pathways leading to inflammation. 
Although they function through a broad and heterogeneous set of mechanisms, the constitutive 
immune responses all function as early barriers to infection and aim to minimize any disruption 
of homeostasis. Supported by recent human and mouse data, in this Review we compare and 
contrast the inducible and constitutive mechanisms of immunosurveillance.
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Constitutive and inducible mechanisms
The innate immune system uses both constitutive and 
inducible mechanisms to eliminate infections and dam-
aged self to maintain homeostasis (Fig. 1). Although the 
constitutive mechanisms have the advantage of provid-
ing an immediate response to a danger signal, they lack 
the potential to amplify the response. In addition, consti-
tutive mechanisms consume energy to remain operative, 
and there are hence limits to how many of these can be 
maintained in any one organism. By contrast, inducible 
mechanisms such as those mediated through PRRs, as 
well as antigen-specific receptors, are activated only 
in response to stimuli and have the ability to amplify 
signals many times. Hence, inducible mechanisms can 
give rise to very strong and efficient immune responses, 
but can also lead to excess inflammation and immuno-
pathology. Given their amplification potential, inducible 
immune mechanisms require tight control and negative 
regulatory systems.
The constitutive immune mechanisms can be divided 
into the chemical and physical barriers of the body, such 
as skin, saliva, stomach acid and urine flow, which are 
not the focus of this Review, and various molecularly 
defined mechanisms that control microbial infection 
and/or replication1. Although these mechanisms have 
been known for many years, they have generally been 
considered to have only minor roles in the immune sys-
tem, and evidence has been lacking as to their specific, 
non-redundant functions in host defence. Consequently, 
they have not received much attention in front-line 
immunology research. Here we discuss the constitu-
tive innate immune responses in comparison with the 
better-described inducible innate responses triggered by 
PRRs. In addition, we present evidence suggesting that 
efficient action of constitutive innate immune mecha-
nisms leads to both antimicrobial activity and mitigation 
of PRR-driven activities (Fig. 2).
PRR-activated inducible innate immune responses. PRRs 
detect pathogen-associated molecular patterns (PAMPs), 
microorganism-associated molecular patterns14, host- 
derived danger-associated molecular patterns15 and 
molecular signatures associated with homeostasis- 
altering molecular processes16. These molecular pat-
terns activate PRR signalling, which ultimately leads 
to the transcription of antimicrobial and proinflam-
matory genes. Downstream activities of PRR signalling 
include the production of type I interferon (interferon-α 
(IFNα) and IFNβ), IL-1β and tumour necrosis factor 
(TNF). These cytokines, in turn, activate antimicrobial 
and proinflammatory activities, as well as the matura-
tion of antigen-specific adaptive immune responses17,18. 
PRR-based immune responses can be highly potent, and 
numerous inflammatory diseases are driven by exces-
sive PRR signalling pathways2,19,20 (Box 1). However, the 
nature of PRR-based immunity is influenced by many 
factors, and it is worth mentioning that the gut micro-
biota and chronic viral infections can induce PRR-based, 
host-beneficial responses that tend towards tolerance 
rather than inflammation21,22. Nevertheless, given the 
potency of PRR-based immunity, full activation of 
PRR-driven immune responses each time a microorgan-
ism is encountered may not be beneficial for an organism 
in the longer term. Moreover, it is essential to control 
the activation and duration of PRR signalling-induced 
activities. This is achieved through multiple mech-
anisms, including two-step procedures for full PRR 
activation23,24, the requirement for a threshold PAMP 
concentration to achieve PRR activation25–28, amplifi-
cation loops from initial low responses29 and numerous 
negative-feedback mechanisms30. One way in which the 
activation of PRR signalling in response to very low levels 
of PAMPs is avoided at the molecular level is through 
supramolecular organizing centres. These are higher-order 
signalling complexes at specific subcellular locations that 
rely on amplification mechanisms to achieve full activa-
tion, thus preventing signalling by subthreshold levels 
of PAMPs but amplifying signalling by superthreshold 
levels of PAMPs29. The double-edged sword-like nature 
of PRR-induced immune responses in terms of their 
roles in both protection and disease is also supported by 
evolutionary evidence. This includes the recurring loss 
of 2′-5′-oligoadenylate synthase 1 (OAS1) in primates31. 
OAS1 is an interferon-inducible protein that is associated 
with both antiviral and pathological activities32,33.
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Fig. 1 | Constitutive innate immune responses versus inducible immune responses. 
Illustration of how constitutive and inducible immune responses vary over time during the 
course of a generalized infection, and their impact on host defence, energy consumption 
and host fitness. In the case of a sterilizing and resolving immune response, the additional 
energy consumption required by the inducible immune response is balanced by the 
re-establishment of homeostasis. By contrast, in the case of an immunopathological 
response, the energy that is consumed to mount an inducible response does not benefit 
the host and instead leads to tissue damage and disruption of homeostasis.
Pattern recognition 
receptors
(PRRs). A family of germline- 
encoded immune receptors, 
including the Toll-like receptors, 
that detect immunostimulatory 
molecules to activate signal 
transduction and gene 
expression, which induces 
antimicrobial and inflammatory 
responses.
Constitutive immune 
mechanisms
Host mechanisms that are 
constitutively present in  
an active or latent form and 
thus can exert host defence 
activities immediately, 
independently of inducible 
processes.
www.nature.com/nri
R e v i e w s
Constitutive innate immune mechanisms. Constitutive 
innate immune mechanisms respond to microbial activi-
ties, cellular stress and metabolic alterations by inducing 
antimicrobial effector functions. As there is most evi-
dence for constitutive innate immune mechanisms that 
exert antiviral and antibacterial activities, these are the 
focus of this Review (Fig. 3). A large range of constitutive 
mechanisms of innate immunity have been identified, 
including restriction factors, antimicrobial peptides, 
basal autophagy and proteasomal degradation (Box 2; 
TABle 1). Here we divide these mechanisms into two 
classes: those that target specific steps in microbial rep-
lication cycles, such as restriction factors34,35, and those 
that lead to degenerative processes, such as autophagy9,36. 
The constitutive mechanisms that target specific steps in 
microbial replication function by blocking molecularly 
defined events that are essential for the replication of 
specific microorganisms but are dispensable for cellu-
lar fitness. By contrast, those mechanisms that operate 
through degenerative programmes target microbial or 
altered host molecules for recycling or degradation. 
The modes of action of representative examples from 
each of these mechanistic classes are described in the 
following sections.
Given the ability of constitutive immune mechanisms 
to exert antimicrobial activity, one consequence of their 
successful action is decreased levels of PAMPs (Fig. 2a). 
This, in turn, limits PRR activation and the down-
stream inflammatory response (Fig. 2b). Thus, constitu-
tive immune mechanisms equip cells and tissues with 
a layer of defence that can fight infections immediately 
and hence potentially limit the requirement for inducible 
immune responses, such as type I interferon, IL-1β and 
other proinflammatory cytokines.
Targeting microbial replication
Direct inhibition of microbial replication is executed by 
molecules that interfere with specific steps in the replica-
tion cycle of a given microorganism. There are at least six 
mechanisms of action in this category: restriction factors 
that directly block a specific replication step; restriction 
factors that deplete molecules essential for replication; 
RNA interference (RNAi); antimicrobial peptides; soluble 
lectins; and metabolite-mediated inhibition of microbial 
replication (TABle 1).
Restrictions factors. Restriction factors are antiviral 
proteins that target viral replication. Extensive studies, 
particularly of HIV-1 and herpesviruses37,38, have led to 
the identification of numerous restriction factors that 
together target nearly all steps in the viral replication 
cycle (Fig. 4a). For example, APOBEC3 proteins belong 
to the family of cytidine deaminases, which catalyse the 
deamination of cytidine to uridine in single-stranded 
DNA, thus introducing potentially deleterious muta-
tions into the HIV-1 genome39. Likewise, tetherin is 
a membrane-bound protein that prevents the release 
of progeny HIV-1 particles from the cell surface40. 
These two mechanisms provide examples of direct 
blockade of specific steps in the replication cycle. By 
contrast, SAM domain and HD domain-containing 
protein 1 (SAMHD1) blocks HIV-1 replication indi-
rectly, by converting deoxynucleoside triphosphates 
into inorganic phosphate and 2′-deoxynucleoside, 
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Fig. 2 | Constitutive innate immune responses negatively regulate 
inducible immune responses. a | Constitutive innate immune mechanisms 
eliminate pathogens during the initial stages of an infection, which 
prevents the accumulation of pathogen-associated molecular patterns 
(PAMPs) that would otherwise activate an inducible immune response 
through pattern recognition receptors (PRRs). In addition, many of the 
constitutive mechanisms are known to directly downregulate PAMP 
signalling through PRRs. Both of these effects limit PRR-induced expression 
of type I interferon and IL-1β. b | The relationship between the different 
proposed layers of the immune response. A first layer of defence is 
exerted by physical and chemical barriers. Constitutive innate immune 
mechanisms function as soon as a danger signal is detected and eliminate 
harmful microorganisms and host molecules by specific non-inflammatory 
mechanisms that operate independently of PRRs. This prevents 
establishment of the infection and accumulation of PAMPs, thus limiting 
the activation of PRR-based inducible innate immune responses. 
If PRR-based immunity is activated, owing to the level of PAMPs exceeding 
a certain threshold, this leads to inflammation and promotes activation 
of the adaptive immune response mediated by T cells and antibodies. 
IRF, interferon regulatory factor.
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thus depleting essential building blocks for HIV-1 
reverse transcription34,41. The aforementioned restric-
tion factors work in the plasma membrane or in the 
cytoplasm. However, many DNA viruses, including 
herpesviruses, replicate in the nucleus, where they are 
also targeted by numerous restriction factors. These 
include nuclear domain 10 bodies (ND10 bodies) and 
IFNγ-inducible protein 16 (IFI16), which operate by 
different mechanisms to epigenetically silence viral 
genomes35,42. The herpesvirus DNA rapidly associates 
with ND10 bodies, which restrict viral gene expression 
by promoting processes that lead to the formation of 
nucleosome-like structures42. IFI16 restricts viral repli-
cation in the nucleus mainly by interfering directly with 
transcription35. New evidence suggests that this involves 
the ability of IFI16 to form DNA filaments, which 
reduces recruitment of RNA polymerase II (ReF.43), but 
also leads to recruitment of ND10 bodies, thus indicat-
ing that these two restriction systems might interact. The 
restriction factors discussed here are all constitutively 
expressed, although the expression of many of them is 
further increased by interferons35,44,45. Tonic type I inter-
feron signalling or constitutive activity of interferon 
regulatory factor 1 (IRF1) drives the basal expression of 
many constitutive restriction factors8,46,47.
RNA interference. RNAi is another constitutive immune 
mechanism that directly controls viral replication. 
RNAi involves the processing of double-stranded RNA 
molecules by members of the Dicer nuclease family to 
20–25-bp fragments, thus leading to the formation of 
the RNA-induced silencing complex (RISC), which 
blocks gene expression or translation through binding 
to target mRNAs48. The ability of RNAi to directly block 
viral replication was first shown in plants49 and was 
later also shown in insects and worms50–52. For example, 
Caenorhabditis elegans and Drosophila melanogaster 
infected with Flock House virus activate antiviral defence 
mechanisms that depend on Dicer51,53. This constitutive 
immune mechanism might have a more important role 
in lower organisms, but as some mammalian viruses do 
target the RNAi system, there may be a subdominant 
role for this primordial antiviral system in host defence 
in more evolved organisms54. For example, Ebola virus 
VP35 and VP30 proteins interact with Dicer cofactors, 
and the hepatitis C virus core protein directly associates 
with Dicer55,56.
Antimicrobial peptides. Antimicrobial peptides, includ-
ing defensins and cathelicidins, contribute to the first 
line of defence against bacteria in the skin and at 
mucosal surfaces. They work by binding directly to bac-
terial membranes, thus perturbing membrane integrity 
and inhibiting microbial growth57–60. These peptides are 
rich in both cationic and hydrophobic amino acids, and 
generally form amphiphilic helical structures, although 
this may not be the case for all antimicrobial peptides61. 
This enables the peptides to interact with negatively 
charged bacterial surfaces through electrostatic inter-
actions, thus triggering disruption of the bacterial 
membranes by pore-forming or non-pore-forming 
mechanisms62. Many antimicrobial peptides, such as 
β-defensin 1, are constitutively expressed on epithelial 
surfaces, thus providing immediate antimicrobial action 
on infection63. This is illustrated by the increased suscep-
tibility to a broad range of bacterial infections in mice 
lacking cathelicidin antimicrobial peptide (CAMP)59,64. 
Beyond their role in antibacterial defence, there is also 
evidence that antimicrobial peptides can disrupt viral 
particles, thus exerting antiviral activity65,66. Similarly 
to the restriction factors, many antimicrobial peptides 
are expressed in both constitutive and inducible man-
ners. This illustrates the general principle that different 
branches of the immune system can use overlapping 
effector functions (Box 2).
Soluble lectins. Many microorganisms have extensive 
and more complex glycan patterns than mammalian 
cells, and these sugars can therefore be used as a means 
to distinguish self from non-self. There are four classes 
of soluble lectins carrying out this function, namely 
collectins, ficolins, galectins and pentraxins67. On reco-
gnition of non-self glycans, soluble lectins can exert 
host defence activities indirectly through complement 
activation and opsonization, as discussed later, or 
directly through aggregation and neutralization. For 
example, the collectin surfactant protein D (SP-D) has 
been reported to bind directly to highly glycosylated 
viruses such as HIV-1 and influenza A virus and neu-
tralize their infectivity68,69. Similarly, pentraxin 3 directly 
binds influenza A virus particles and neutralizes virus 
infectivity70. Importantly, SP-D-deficient mice have 
impaired clearance of influenza A virus and increased 
production of proinflammatory cytokines in response to 
viral challenge71. In addition to viruses, SP-D also binds 
and agglutinates Streptococcus pneumoniae72, thus sug-
gesting that soluble lectins might also have a role in the 
immediate inactivation of bacteria.
Box 1 | Diseases induced by excessive production of Il-1 and type I interferon
excessive or prolonged activation of pattern recognition receptor (Prr) signalling  
is associated with a range of human diseases. several cytokines are involved in 
Prr-driven diseases, including tumour necrosis factor (tNF), iL-1β, iL-6 and type i 
interferon169,170. among these, iL-1β and type i interferon are induced exclusively by  
Prr signalling. thus, the existence of human diseases that are mediated by these two 
classes of cytokines provides strong evidence for the pathological potential of 
Prr-based immune responses. Here we describe some examples of sterile inflammation 
involving iL-1β and type i interferon. we now know that diseases such as familial 
Mediterranean fever, tNF receptor-associated periodic syndrome, hyper-igD syndrome 
and cryopyrin-associated periodic syndrome are characterized by increased expression 
of iL-1β; furthermore, blocking iL-1-induced signalling in these disease can relieve 
clinical symptoms and improve disease outcome171. similarly, diseases such as aicardi–
Goutières syndrome, stimulator of interferon gene (stiNG)-associated vasculopathy 
with onset in infancy, sjögren syndrome, proteasome-associated autoinflammatory 
syndromes and systemic lupus erythematosus are associated with high levels of 
expression of interferon-stimulated genes (known as an ‘interferon signature’) and  
are termed ‘interferonopathies’, although the precise contribution of the interferon 
signature to disease pathogenesis is not completely understood170. For several of these 
diseases, inhibition of Janus kinase 1 (JaK1) and JaK3, which are involved in interferon- 
induced signalling, significantly reduces disease activity172. there are marked 
differences in the pathogenesis of iL-1-driven diseases and interferon-driven diseases. 
Diseases that depend on iL-1 are generally neutrophilic and associated with fever and 
increased levels of acute phase reactants, whereas interferon-driven diseases are 
characterized mainly by lymphopenia, vasculitis, central nervous system manifestations 
in some diseases, skin manifestations and varying levels of autoantibodies171,173.
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Metabolite-mediated inhibition. A final example of 
constitutive immune mechanisms that directly inter-
fere with microbial growth is provided by metabolites 
that block pathogen replication, and perhaps the best 
example of which is lactate73,74. Many viral infections 
are characterized by a shift of host cellular metabolism 
to aerobic glycolysis, which leads to the production of 
lactate75,76. Viral infections also induce fatty acid synthe-
sis and intermediate molecules in these pathways. These 
include palmitic acid and oleic acid, which have been 
shown to have antiviral activity77,78. The mechanisms by 
which lactate and other metabolites block viral replica-
tion remain to be determined, but the antiviral activity of 
lactate illustrates a general principle that select molecules 
accumulating during alterations of cellular homeostasis 
can interfere with microbial replication.
A second form of metabolite-dependent constitutive 
host defence is mediated through nutritional deple-
tion and starvation of pathogens. For example, natural 
resistance-associated macrophage protein 1 (NRAMP1; 
also known as SLC11A1) is a metal ion transporter that 
transports divalent cations from vacuoles into the cyto-
plasm, hence depleting factors from vacuoles that are 
essential for the growth of intracellular pathogens79. The 
gene encoding NRAMP1 was shown to contribute to 
defence against, for example, Mycobacterium tuberculosis, 
Salmonella enterica subsp. enterica serovar Typhimurium 
and Leishmania donovani80,81, which was later shown to 
be mediated by the reduction of metal ion concentra-
tions inside microorganism-containing vacuoles82. 
A second example of nutritional depletion is provided by 
lactoferrin, which is present in various secretory fluids. 
Lactoferrin is a highly cationic molecule that shows anti-
microbial activity, in part, by binding and sequestering 
iron from pathogenic microorganisms83. Lactoferrin 
contributes to host defence in a non-redundant man-
ner, as lactoferrin-deficient mice have increased suscep-
tibility to Streptococcus mutans-induced dental caries, 
for example84.
Degenerative mechanisms
The second class of constitutive innate immune mech-
anisms functions through the degradation of danger 
molecules and elimination of unwanted cells. This 
class of mechanisms includes autophagy, phagocyto-
sis, proteasomal degradation and nucleases (TABle 1). 
Collectively, degenerative programmes function to 
continually limit danger signals, allowing for the rapid 
elimination of unwanted molecules without the acti-
vation of energy-consuming amplificative induced 
immune responses.
Autophagy and phagocytosis. Autophagy and phagocy-
tosis execute the digestion of intracellular and extracel-
lular microorganisms, respectively, through membrane 
encapsulation followed by chemical and enzymatic 
degradation85,86. Pathogens are shunted into these 
pathways through the recognition of polyubiquitin 
chains or glycans inside damaged vacuoles in the case 
of autophagy9,87, and through complement coating of 
microorganisms in the case of phagocytosis88. In the 
case of autophagy, a large number of ubiquitin E3 ligases 
have been identified that coat viral and bacterial surfaces 
with ubiquitin9,89–92, thus targeting microorganisms for 
loading into autophagosomes through interaction with 
the autophagosome-associated protein LC3 (also known 
as MAP1ALC3)85 (Fig. 4b). This targeting mechanism 
involves E3 ligases, including SMURF1 and LRSAM1 
(ReFs91,92), as well as the ubiquitin-binding selective auto-
phagy receptors p62 (also known as SQSTM1), optineu-
rin and NDP52 (also known as CALCOCO2)9,89,93. An 
alternative mechanism for sensing of vesicle-damaging 
pathogens has been identified that involves damaged 
vesicles exposing glycans in the cytoplasm for sensing by 
galactin 8, which links to autophagy via NDP52 (ReF.87). 
This triggers phagophore formation in the vicinity of 
cytosolic bacteria94. Autophagy has important roles in 
the control of infection. For example, defective autophagy 
leads to increased susceptibility to infection with Sindbis 
virus in mice89. In addition, stimulation of autophagy 
in primary human macrophages mediated protection 
against M. tuberculosis infection95,96. However, mice defec-
tive in autophagy do not have impaired antimycobacterial 
defence in vivo, which indicates that the precise role of 
autophagy requires further investigation97. Third, herpes 
simplex virus type 1 specifically interferes with autophagy, 
which is essential for neuropathogenicity of the virus36.
Complement-mediated phagocytosis involves spe-
cific recognition of complement components bound 
to the surface of microorganisms by the corresponding 
complement receptors on phagocytes. Activation of 
the complement system, for example after sensing of gly-
cans by the lectin pathway, leads to the formation of C3 
convertase, eventually generating C3b, which binds 
to complement receptors, thus inducing phagocytosis98. 
Mice devoid of the lectin-based complement path-
way have increased susceptibility to Staphylococcus 
aureus infection and impaired bacterial phagocytosis99. 
Furthermore, several bacteria, including Streptococcus 
pyogenes, inhibit complement-mediated phagocytosis100.
A third degenerative mechanism for the degradation 
of membrane-encapsulated extracellular material is 
LC3-associated phagocytosis (LAP), which uses com-
ponents from both the phagocytosis and autophagy 
pathways101. LAP is involved in the clearance of extra-
cellular pathogens and dead cells102, and LAP-deficient 
mice fail to clear Aspergillus fumigatus infection103. Thus, 
autophagy, phagocytosis and LAP are important systems 
for immediate host defence.
Proteasomal degradation. The proteasome is a cyto-
plasmic protein complex that degrades proteins by 
proteolysis104. Proteins to be degraded are tagged 
by K48-linked polyubiquitylation, attracted to the pro-
teasome, unfolded into polypeptides and then degraded104. 
The proteasomal degradation pathway also contrib-
utes to immediate defence against infecting pathogens. 
For example, viruses can be detected by the ubiquitin 
E3 ligase TRIM21 through binding to antibody-bound 
viral capsids, which links to downstream proteasomal 
degradation105. This process is involved in the elimina-
tion of infecting viral capsids from the cytoplasm and 
contributes to antiviral defence105–107. Other studies have 
shown that the viral RNA-dependent RNA polymerase of 
Aerobic glycolysis
The process by which glucose 
is converted to lactate in the 
presence of oxygen to produce 
energy in the form of ATP.
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turnip yellow mosaic virus is degraded by the ubiquitin–
proteasome pathway to control infection108. Proteasome 
activity also contributes to defence against many bacte-
rial infections, including Yersinia spp. infections109, and 
the ubiquitin–proteasome pathway is targeted by many 
viruses and bacteria to promote replication110–114. For 
example, the human cytomegalovirus protein pUL25 
inhibits proteasomal degradation of another viral pro-
tein, pUL26, to sustain the activity of a pUL26-mediated 
immune evasion mechanism114. Collectively, these exam-
ples show that the conserved proteasome pathway is part 
of the constitutive immune defence repertoire.
Nucleases. The cytoplasm contains RNAses and DNAses 
that eliminate unwanted nucleic acid species, including 
viral nucleic acids, and these enzymes can thereby con-
tribute to sterilization of the cytoplasm. RNase L is a 
latent cytoplasmic exoribonuclease that is activated by 
2′-5′ oligoadenylates produced by OASs115. Although 
OASs are highly interferon inducible, they are also 
expressed at a basal level and hence induce basal RNase L 
activity116. Importantly, this activity has been suggested 
to contribute to basal restriction of coronaviruses in 
myeloid cells, and hence to protect other cell types from 
infection117. TREX1 is a cytoplasmic exodeoxyribonu-
clease that eliminates DNA from the cytoplasm. Very 
few microorganisms have free DNA as part of their 
productive replication cycle, but exogenous and endog-
enous retroviruses have a cytoplasmic DNA step that 
is sensitive to degradation by TREX1. Consequently, 
Trex1–/– mice have increased levels of endogenous ret-
roviral DNA in the cytoplasm118, which indicates that 
TREX1 has a role in limiting retroviral infection and 
hence maintaining genome integrity.
Limiting inflammatory responses
Immune responses induced by PRRs and by antigen- 
specific receptors are often highly potent and sterilizing. 
However, they may also be relatively disruptive and can 
be associated with tissue damage and the requirement 
for significant tissue repair and energy consumption119. 
Many of the constitutive immune mechanisms discussed 
here not only interfere with microbial replication but 
also have negative effects on PRR activity (TABle 1). This 
raises the possibility that an overarching function of the 
constitutive immune mechanisms is to both eliminate 
danger and limit the use of PRR-driven activities. At the 
mechanistic level, this immunoregulatory function of 
the constitutive mechanisms can be exerted in two qual-
itatively different ways. The first is through the direct 
effect of their antimicrobial activity on decreasing levels 
of PAMPs. The second is through specific inhibition of 
PRR signalling.
Reduction of PAMP levels. Many studies have shown 
that PRR activation requires PAMP levels to be above 
a certain threshold25–28. Above this threshold, PRRs are 
activated in a concentration-dependent manner until 
saturation is reached. Therefore, constitutive immune 
mechanisms that reduce PAMP levels will limit or even 
prevent PRR activation (Fig. 2a). For example, mice 
deficient in the restriction factor APOBEC3, which has 
antiretroviral activity, have higher viral loads after infec-
tion with murine leukaemia virus and corresponding 
higher levels of reverse viral transcripts and downstream 
interferon induction through the cgAs–sTiNg pathway 
(cyclic GMP–AMP synthase–stimulator of interferon 
genes pathway)120. Similarly, SAMHD1 activity in vivo 
controls lentivirus load and limits virus-induced pro-
duction of interferons in myeloid cells121. In addition, 
SAMHD1 deficiency leads to increased expression of 
costimulatory molecules and T cell activation on len-
tiviral infection, which suggests that the constitutive 
reduction of PRR activation by SAMHD1 limits not 
only the expression of innate immune cytokines but 
also downstream adaptive immune responses121. A third 
example is provided by the observation that expres-
sion of Drosophila Dicer in mammalian cells leads to 
decreased induction of IFNβ by double-stranded RNA, 
most likely owing to the digestion of immunostimu-
latory RNA into shorter 20–25-bp RNA species that 
activate PRRs only inefficiently122. Finally, constitutive 
innate immune mechanisms can also reduce PRR activ-
ity by lowering the concentration of PAMPs that have 
immunostimulatory activity. For example, lactoferrin 
binds CpG DNAs and inhibits their ability to activate 
TLR9 (ReF.123).
Inhibition of PRR signalling. In addition to reducing the 
levels of PAMPs, some constitutive mechanisms have 
been reported to target PRR activity at the signalling 
level (Fig. 2a). For example, autophagy negatively reg-
ulates signalling by the Rig-i–MAVs pathway (retinoic 
acid-inducible gene I protein–mitochondrial antiviral 
signalling protein pathway) and by the cGAS–STING 
pathway; in the former case by limiting reactive oxygen 
species-mediated amplification of signalling and by 
LC3-dependent MAVS inactivation124,125, and in the 
latter case through degradation of STING126. In line 
with this, defective autophagy as a result of ATG16L 
deficiency predisposes to STING-dependent intestinal 
pathology in mice127, and ATG5 deficiency selectively in 
Fig. 3 | overview of the regulation of microbial replication by constitutive innate 
immune mechanisms. a | Constitutive innate immune mechanisms and viral infection. 
The accumulation of specific viral molecular structures (such as double-stranded 
RNA (dsRNA) or capsids) and cellular stress responses (such as autophagy) activate 
constitutive–latent mechanisms with direct antiviral activity, independently of pattern 
recognition receptors. Some of the antiviral effector functions target microbial 
replication by blocking specific steps in the replication cycles of viruses; these effectors 
include soluble lectins, antimicrobial peptides, restriction factors, RNA interference 
(RNAi) and metabolites. Other antiviral effectors of the constitutive response function 
through the degradation of virus particles; these include nucleases such as TREX1, which 
degrades viral DNA in the cytoplasm, and RNase L, which degrades viral RNA, as well 
as autophagy and proteasomal degradation. Viruses can be targeted for proteasomal 
degradation by the ubiquitin E3 ligase TRIM21, which binds to antibody-attached 
viral capsids. b | Constitutive innate immune mechanisms and bacterial infection. 
The presence of bacteria changes the local microenvironment, for example through the 
accumulation of hydrophobic and charged bacterial surfaces or alteration of cellular 
metabolism. This activates antibacterial activities independently of pattern recognition 
receptors, including inactivation by soluble lectins and antimicrobial peptides, nutritional 
depletion by natural resistance-associated macrophage protein 1 (NRAMP1) and 
lactoferrin, and bacterial degradation by phagocytosis and basal autophagy. dsDNA, 
double-stranded DNA; RISC, RNA-induced silencing complex; ROS, reactive oxygen 
species; viRNA, virus-derived small interfering RNA.
◀
cGAS–STING pathway
(Cyclic gMP–AMP synthase–
stimulator of interferon genes 
pathway). cgAs is a cytosolic 
DNA-sensing pattern 
recognition receptor that 
signals via sTiNg to induce the 
expression of type i interferon 
and inflammatory cytokines.
RIG-I–MAVS pathway
(Retinoic acid-inducible gene i 
protein–mitochondrial antiviral 
signalling protein pathway). 
Rig-i is a cytosolic RNA-sensing 
pattern recognition receptor 
that signals via MAVs to 
induce the expression of type i 
interferon and inflammatory 
cytokines.
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neutrophils exacerbates M. tuberculosis immunopathol-
ogy without affecting bacterial load97. As a second exam-
ple, lactate, which is produced during aerobic glycolysis 
and has virus-restricting activity73,74, also directly inhib-
its MAVS activity; thus lactate both reduces levels of viral 
PAMPs and has a negative regulatory function to inhibit 
PAMP-driven signalling and interferon expression128. 
Third, an engineered amphipathic-helical antimicro-
bial peptide was found to block TLR4 signalling through 
the TRIF pathway129. This occurs by the inhibition of 
TLR4 endocytosis, which is an essential step for the 
engagement of TRIF from endosomal compartments.
Collectively, the current literature suggests that con-
stitutive immune mechanisms reduce PRR activation 
through a range of mechanisms and, therefore, that these 
constitutive mechanisms impose a threshold and negative 
regulatory activity on the amplificative innate and adap-
tive immune responses (Fig. 2b). We propose that rapid, 
molecularly specific and non-amplificative responses to 
challenges provided by constitutive immune mechanisms 
are beneficial for achieving optimal host defence with 
minimal immunopathology.
Constitutive immunity beyond infection
Our main focus here has been on infections. However, 
constitutive immune mechanisms are also involved in the 
elimination of sterile danger. For example, DNA damage in 
the nucleus and the accumulation of DNA in extranuclear 
compartments are eliminated by the DNA damage response 
and specific DNases130, respectively; the accumulation 
of misfolded proteins leads to the formation of aggre-
somes, which are cleared by selective autophagy131,132; 
excessive accumulation of reactive oxygen species leads 
to death of the oxygen-stressed cells133; and free choles-
terol is converted into an ester derivative by lecithin– 
cholesterol acyltransferase, thus enabling transport 
to the liver by high-density lipoprotein and eventual 
degradation134. Defects in these constitutive and latent 
danger-eliminating mechanisms lead to the accumulation 
of danger-associated molecular patterns and activation of 
PRR-based immunity. For example, in cells with defects in 
either the DNA damage response or extranuclear DNases, 
the accumulation of DNA induces type I interferon 
production through the cGAS–STING pathway135–138. 
Similarly, defective elimination of protein aggregates 
or cholesterol leads to the induction of IL-1β produc-
tion through activation of the NlRP3 inflammasome139,140. 
Common to all of the examples given above is that the 
accumulated abnormal endogenous molecules are 
detected and eliminated through molecularly specific 
mechanisms independently of PRRs. This elimination 
limits PRR activation and hence inflammatory reactions. 
Therefore, in addition to eliminating microorganisms and 
PAMPs, constitutive immune mechanisms also eliminate 
sterile danger signals in a damage-limiting manner that 
prevents the activation of excessive inflammation.
Constitutive immunity in human health
We propose that constitutive immune mechanisms 
enable cells and organisms to fight infections and elim-
inate endogenous abnormalities in a non-inflammatory 
manner. Therefore, an important benefit of these mech-
anisms may be to increase the threshold for develop-
ment of clinically overt signs of disease on exposure to 
infections or endogenous danger. Studies of the associ-
ations between single-nucleotide polymorphisms and 
infections have shown that restriction factors, antimi-
crobial peptides and autophagy have important roles 
in antimicrobial defence141–144. Constitutive immune 
mechanisms may be particularly active in the protec-
tion of tissues that are frequently exposed to pathogens, 
such as epithelial cells in the airways and the gut, or 
tissues that are particularly vulnerable to immuno-
pathology, such as the brain. In favour of this idea, RNA 
lariat debranching enzyme 1 (DBR1) and small nucle-
olar RNA, H/ACA box 31 (SNORA31) were recently 
shown to have non-redundant, interferon-independent 
roles in the prevention of viral brainstem encephali-
tis and herpes simplex encephalitis, respectively11,12. 
The mechanisms through which they exert their anti-
viral activity remain to be determined. Reports have 
shown that autophagy is an antiviral mechanism in the 
brain in mice36,89,145. In addition, some cell populations, 
including stem cells, seem to use constitutive immune 
mechanisms to eliminate danger without losing key 
functions, such as self-renewal and differentiation 
capacity, that are known to be impaired by PRR-based 
immunity146,147.
An important question related to human immuno-
logy is how individuals with a loss-of-function mutation 
in a constitutive immune mechanism may present clini-
cally. Deficiency of a mechanism that is expressed in spe-
cific organs or cell types might lead to a higher frequency 
of clinical infections by a subset of microorganisms that 
are normally controlled by the defective mechanism. 
This seems to be the case for defects in DBR1, which 
confer susceptibility to disease caused by infections with 
herpes simplex virus type 1, influenza virus or norovirus 
in the brainstem11. The impact of deficiencies in constitu-
tive immune mechanisms might not be limited to acute 
infections and could also include chronic and latent infe-
ctions. In support of a link between such defects and 
increased inflammation, patients with inborn defects in 
DNA repair, elimination of extranuclear DNA or degra-
dation of misfolded proteins develop autoinflammatory 
DNA damage response
Cellular response to DNA 
damage, including the 
re-establishment of genome 
integrity and cell death 
responses.
NLRP3 inflammasome
The NlRP3 inflammasome is 
activated by danger-associated 
molecular patterns and 
molecular signatures 
associated with homeostasis- 
altering molecular processes  
to execute caspase 1-mediated 
cleavage of molecules such  
as pro-il-1β and gasdermin D.
Box 2 | overlap between constitutive and inducible immune responses
in most respects, constitutive and inducible immune responses operate through 
different principles; however, in certain cases, their downstream effector activities may 
overlap. this is to be expected given that all of these responses use mechanisms from 
the same ‘evolutionary toolbox’ to achieve optimal protection of the host. For example, 
autophagy can be activated during infection and upon sterile danger9,174. similarly, 
phagocytosis can be activated by both toll-like receptor (tLr)-dependent and tLr- 
independent mechanisms175–177. Moreover, many restriction factors are expressed at 
basal levels to exert immediate antiviral activity, but are also induced transcriptionally 
in response to stimulation with type i interferon35,40,178. Nevertheless, despite these 
minor areas of overlap between constitutive immune mechanisms and the pattern 
recognition receptor (Prr)-induced immune responses, the differences are more 
pronounced. the key difference between constitutive immune mechanisms and Prr- 
induced immunity is that the former mechanisms are all activated through pre-existing 
molecules to directly eliminate danger, whereas the latter system functions mainly 
through inducible transcription-dependent proinflammatory programmes. in addition, 
inducible innate responses can amplify adaptive responses, whereas constitutive innate 
responses do not amplify inducible innate responses.
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diseases, including Aicardi–Goutières syndrome and 
proteasome-associated autoinflammatory syndromes, 
which are characterized by type I interferon-dependent 
autoinflammation and are termed ‘interferonopa-
thies’137,148–150. Therefore, a loss of function in constitutive 
immune mechanisms can lead to selective susceptibility 
to specific infections or to infections in specific organs. 
Likewise, such deficiency might lead to the accumula-
tion of PAMPs, microorganism-associated molecular 
patterns, danger-associated molecular patterns and/or 
Table 1 | Constitutive immune mechanisms in host defence
Type of 
effector
Examples Trigger Target microorganisms Evidence for control of 
inflammatory responses
Refs
Targeting microbial replication
Restriction 
factors
BST2, YBX1, IFITMs Specific viral 
replication events
HIV-1, HCV, HSV-1, VSV, RSV Increased IL-6 and IL-1β expression 
in the lungs of RSV-infected Ifitm1–/– 
mice; increased constitutive infiltration 
of monocytes and macrophages in the 
kidney in Ybx1–/– mice
40,44, 
154–156
SAMHD1, APOBEC3 Modulation of nucleic 
acid availability and/or 
function
HIV-1, vaccinia virus, HSV-1, 
murine herpesvirus 68, 
parvovirus
Increased spontaneous and 
lentivirus-induced interferon and 
ISG expression in Samhd1–/– mice; 
increased IFNβ expression in 
Apobec3–/– mice infected with murine 
leukaemia virus
39,41,120, 
121,157,158
RNAi RISC dsRNA Cucumovirus (plants), Flock 
House virus (worms), cricket 
paralysis virus (flies)
Introduction of Drosophila Dicer-2 
in mammalian cells reduced 
dsRNA-induced IFNβ expression
50–52,159
Antimicrobial 
peptides
β-Defensins, 
cathelicidin
Negatively charged 
surfaces
Salmonella enterica subsp. 
enterica serovar Typhimurium, 
Escherichia coli, Shigella spp., 
HIV-1
LL37 inhibits DNA-sensing 
inflammasomes in psoriatic skin;  
an engineered antimicrobial peptide 
inhibits TLR4 signalling through  
the TRIF pathway
58–60,65, 
129,160
Soluble lectins Collectins, ficolins, 
galectins, pentraxins
Glycans HIV-1, influenza A virus, 
Streptococcus pneumoniae
SP-A inhibits LPS-induced TLR4 
activation by preventing the 
interaction with LPS-binding protein; 
SP-D-deficient mice have increased 
levels of proinflammatory cytokines 
after influenza virus infection
68–72,161
Metabolites Lactate, palmitic acid Metabolic alterations HIV-1, HSV-1, Zika virus, VSV Ldha–/– mice express increased levels of 
type I interferon on infection with RNA 
viruses
73,74,77, 
162,163
NRAMP1, lactoferrin Iron depletion Mycobacterium tuberculosis, 
S. Typhimurium, Leishmania 
donovani, Streptococcus 
mutans
Lactoferrin binds CpG DNA and 
impedes stimulation through TLR9
80,81, 
84,123
Degenerative mechanisms
Autophagy – Viral proteins, 
organelle dysfunction, 
protein aggregates
M. tuberculosis,  
S. Typhimurium, Sindbis virus
Increased interferon expression 
and inflammasome activation in 
autophagy-defective cells; excess IL-1β 
production and lung inflammation 
in autophagy-deficient mice after 
infection and sterile challenge
9,89,96, 
126,164
Phagocytosis – Opsonization Staphylococcus aureus, 
Salmonella spp., Mycobacteria 
spp., Aspergillus spp.
Patients with CGD have increased 
inflammasome activity and IL-1β 
production
165,166
LC3-associated 
phagocytosis
– Not known S. Typhimurium, Listeria 
monocytogenes, Burkholderia 
pseudomallei
LC3-deficient mice fail to clear 
dead cells and develop lupus-like 
inflammatory disease
102,123, 
167,168
Proteasomal 
degradation
– Cytosolic capsids and 
capsid–IgG complexes
Adenovirus, turnip yellow 
mosaic virus
Patients with PRAAS-associated 
mutations in proteasome genes have 
strong interferon signatures
105–107, 
111,148,149
Nucleic acid 
degradation
– Cytosolic RNA  
and DNA
Endogenous retroviruses, 
murine coronaviruses
Patients with defective TREX1 have 
increased interferon expression and 
develop Aicardi–Goutières syndrome
117,118,137
APOBEC3, apolipoprotein B mRNA-editing complex 3; BST2, bone marrow stromal antigen 2 (also known as tetherin); CGD, chronic granulomatous disease; 
dsRNA, double-stranded RNA; HCV, hepatitis C virus; HSV-1, herpes simplex virus type 1; IFITMs, interferon-induced transmembrane proteins; ISG, 
interferon-stimulated gene; Ldha, lactate dehydrogenase A; LPS, lipopolysaccharide; NRAMP1, natural resistance-associated macrophage protein 1; PRAAS, 
proteasome-associated autoinflammatory syndromes; RISC, RNA-induced silencing complex; RNAi, RNA interference; RSV, respiratory syncytial virus; SAMHD1, 
SAM domain and HD domain-containing protein 1; SP, surfactant protein; TLR, Toll-like receptor; VSV, vesicular stomatitis virus; YBX1, Y-box binding protein 1.
Nature reviews | Immunology
R e v i e w s
Herpesvirus
a  Restriction factors
b
Retrovirus
Tegument
MTOCTRIM43
MX2
MX2
TRIM5α
IFITM
SERINC3/
SERINC5
APOBEC3
SAMHD1
SLFN11
MARCHF8
BST2
p62
p62
SMURF1
NDP52
Optineurin
LRSAM1
TRIM23
Pericentrin
Degradation
Replication
Lamina
disruption
Assembly
and egress
Transcription
Integration
ND10 
body
Galectin 8
BST2 Transcription
Reverse
transcription
Viral RNA
LC3p62
Ubiquitylated 
bacterium
Ubiquitylation
Cargo 
loading
Cytosolic 
glycan
exposure
Degradation
Autophagosome–
lysosome fusion
Ub
Ub
Ub
Ub
Ub
Ub
SNORA31DBR1
SIRT6
SAMHD1
IFI16
Pathogen-
damaged vesicle
Fig. 4 | Constitutive control of microbial replication by restriction factors and autophagy. a | Restriction factors that control herpesvirus and retrovirus 
infections, including their targets in the viral replication cycle. Restriction factors interfere with viral replication by either blocking a specific and essential step 
in the viral replication cycle (for example, viral gene transcription or release of progeny virus) or depletion of factors that are essential for replication (such as 
deoxynucleoside triphosphates). b | Blockade of viral and bacterial replication by autophagy. Various ubiquitin E3 ligases (such as SMURF1, LRSAM1 and 
TRIM23) and ubiquitin-binding proteins (such as p62, optineurin and NDP52) have been identified to conjugate ubiquitin to microbial surfaces, which targets 
them for loading into autophagosomes. Also, cytosolic exposure of glycans by pathogen-damaged vesicles can be recognized by galectin 8 for targeting to 
autophagosomes. APOBEC3, apolipoprotein B mRNA-editing complex 3; BST2, bone marrow stromal antigen 2 (also known as tetherin); DBR1, RNA lariat 
debranching enzyme 1; IFI16, interferon-γ-inducible protein 16; IFITM, interferon-induced transmembrane protein; MTOC, microtubule-organizing centre; 
ND10, nuclear domain 10; SAMHD1, SAM domain and HD domain-containing protein 1; SIRT6, sirtuin 6; SNORA31, small nucleolar RNA, H/ACA box 31.
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homeostasis-altering molecular processes and associated 
pathological inflammation (Box 1).
Outlook
In this article, we have described the role and mode of 
action of a large panel of constitutive mechanisms used 
by the immune system to exert immediate control of 
infections and endogenous dangers independently of the 
inducible mechanisms that are activated through PRRs 
and antigen-specific receptors. Although many such 
constitutive responses have been known for years, 
greater understanding of the mechanisms involved 
and renewed interest in fields such as restriction factor 
biology and immunometabolism are spurring further 
work in the area. With the identification of constitu-
tive mechanisms that have non-redundant roles in 
host defence, we now know that these immune mech-
anisms are not just redundant, non-specific players 
in immunology11,12. This should stimulate interest in 
understanding the roles played by constitutive immune 
mechanisms in host defence in vivo, which might 
include the identification of new primary immune dis-
orders. Improved knowledge of the host cell type and 
tissue specificities of constitutive immune mechanisms 
in relation to susceptibility to infections could greatly 
improve our understanding of human immunology. 
Such work will start to provide answers to the funda-
mental question of how the immune system determines 
the degree of threat caused by an infection and bal-
ances that with the appropriate strength of the immune 
reaction.
Finally, as we gain further insights into the various 
host responses that are activated during immunologi-
cal challenge, it will be interesting to explore the idea 
that the immune system has a defensive layer of activ-
ities that have been selected to eliminate danger with-
out engaging the PRR system (Box 3). In this respect, 
it is interesting to note that in addition to the consti-
tutive mechanisms described in this Review, there 
are various sensing systems that use transcriptional 
programmes to induce host defence independently of 
PRRs and with the ability to control inflammation. They 
include the NRF2–KeAP1, hypoxia-inducible factor 1α and 
bone morphogenetic protein–sMAD pathways10,151–153. 
In addition, the constitutive host defence exerted by 
commensal bacteria through several mechanisms, 
including niche competition, warrants more attention. 
With more and more data emerging on the importance 
of constitutive mechanisms in immunology, there is a 
need to understand this phenomenon in more detail. 
Such work may advance our understanding of one of 
the most interesting questions in immunology, namely 
how to eliminate danger in a rapid, efficient and specific 
manner without causing excess damage to the host.
Published online xx xx xxxx
NRF2–KEAP1
Nuclear factor erythroid 
2-related factor 2 (NRF2) 
senses oxidative stress, 
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Kelch-like eCH-associated 
protein 1 (KeAP1) to 
translocate to the nucleus 
and induce gene expression.
Hypoxia-inducible factor 1α
A transcription factor that is 
activated by hypoxia to induce 
the expression of genes with 
hypoxia-responsive elements 
in their promoters.
Bone morphogenetic 
protein–SMAD
Bone morphogenetic proteins 
are growth factors that signal 
through sMAD proteins to 
induce gene transcription.
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